TY - JOUR
T1 - Clinical significance of Candida isolation from dystrophic fingernails
AU - Shemer, Avner
AU - Daniel, Ralph
AU - Lyakhovitsky, Anna
AU - Aghion-Svirsky, Vered
AU - Kassem, Riad
AU - Rigopoulos, Dimitris
AU - Farhi, Renata
AU - Galili, Eran
N1 - Publisher Copyright:
© 2020 Blackwell Verlag GmbH
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Candida onychomycosis mostly involves fingernails. Yet, in contrast to dermatophytes, Candida isolation from dystrophic fingernails does not prove casualty, as sample contamination and non-pathogenic Candida growth occur. Characterising treatment outcome of Candida-positive dystrophic nails is crucial to avoid unnecessary treatment. Objective: To investigate predicators associated with treatment outcome among Candida-positive dystrophic fingernails. Patients and methods: A retrospective cohort study was carried out among 108 adults with Candida-positive dystrophic fingernails not cured with adequate systemic anti-fungal course. Diagnosis was based on a single mycological culture. Patients with treatment failure (n = 85; 78.7% of the cases) were compared to patients with partial response (mild to almost cure; n = 23; 21.3% of the cases) at 9 to 12 months following treatment initiation. Results: Treatment failure was significantly associated with primary onycholysis (odds ratio [OR] 2.8; 95% confidence interval [CI] 1.1-7.4) and prolonged dystrophy (12.8 vs. 3.7 years in average), compared to partial treatment response. Non-responders had lower odds to present with distal lateral subungual onychomycosis, compared to partial responders (OR 0.3; 95% CI 0.1-0.7). Demographic and mycological characteristics, as well as number of nails affected, co-presence of paronychia, and treatment regime were not found to be associated with treatment response. Conclusion: Candida-positive primary onycholysis was shown to be non-responsive to systemic anti-fungal treatment, suggesting that anti-fungal treatment is not indicated. For other clinical scenarios, high proportions of treatment non-response suggest that determining causality of Candida should not be based on a single positive mycological culture.
AB - Background: Candida onychomycosis mostly involves fingernails. Yet, in contrast to dermatophytes, Candida isolation from dystrophic fingernails does not prove casualty, as sample contamination and non-pathogenic Candida growth occur. Characterising treatment outcome of Candida-positive dystrophic nails is crucial to avoid unnecessary treatment. Objective: To investigate predicators associated with treatment outcome among Candida-positive dystrophic fingernails. Patients and methods: A retrospective cohort study was carried out among 108 adults with Candida-positive dystrophic fingernails not cured with adequate systemic anti-fungal course. Diagnosis was based on a single mycological culture. Patients with treatment failure (n = 85; 78.7% of the cases) were compared to patients with partial response (mild to almost cure; n = 23; 21.3% of the cases) at 9 to 12 months following treatment initiation. Results: Treatment failure was significantly associated with primary onycholysis (odds ratio [OR] 2.8; 95% confidence interval [CI] 1.1-7.4) and prolonged dystrophy (12.8 vs. 3.7 years in average), compared to partial treatment response. Non-responders had lower odds to present with distal lateral subungual onychomycosis, compared to partial responders (OR 0.3; 95% CI 0.1-0.7). Demographic and mycological characteristics, as well as number of nails affected, co-presence of paronychia, and treatment regime were not found to be associated with treatment response. Conclusion: Candida-positive primary onycholysis was shown to be non-responsive to systemic anti-fungal treatment, suggesting that anti-fungal treatment is not indicated. For other clinical scenarios, high proportions of treatment non-response suggest that determining causality of Candida should not be based on a single positive mycological culture.
KW - Candida
KW - anti-fungal treatment
KW - azole
KW - fingernail
KW - fingernail dystrophy
KW - onycholysis
KW - onychomycosis
KW - treatment efficacy
UR - http://www.scopus.com/inward/record.url?scp=85087439625&partnerID=8YFLogxK
U2 - 10.1111/myc.13133
DO - 10.1111/myc.13133
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32563206
AN - SCOPUS:85087439625
SN - 0933-7407
VL - 63
SP - 964
EP - 969
JO - Mycoses
JF - Mycoses
IS - 9
ER -